Jazz Pharmaceuticals (JAZZ) EBIT (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly EBIT of $336.6 million for Q1 2026, up 702.15% year-over-year from $42.0 million in Q1 2025, and up 32.24% quarter-over-quarter from $254.5 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) EBIT (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' EBIT history runs 17 years deep, the most recent figure standing at $336.6 million for Q1 2026.
- In Q1 2026, EBIT rose 702.15% year-over-year to $336.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 106.35% YoY), while the FY2025 annual figure was -$430.2 million, down 160.04% from the prior year.
- EBIT for Q1 2026 stood at $336.6 million, up from $254.5 million in the prior quarter.
- The five-year high for EBIT was $336.6 million in Q1 2026, with the low at -$686.4 million in Q2 2025.
- The 5-year median for EBIT is $122.5 million (2023), against an average of $66.8 million.
- The sharpest annual moves came in 2022 and 2026: EBIT tumbled 633.39% in 2022, then surged 702.15% in 2026.
- Jazz Pharmaceuticals' EBIT stood at -$263.4 million in 2022, then jumped by 146.51% to $122.5 million in 2023, then surged by 55.73% to $190.8 million in 2024, then soared by 33.43% to $254.5 million in 2025, then jumped by 32.24% to $336.6 million in 2026.
- Business Quant data shows JAZZ's EBIT at $336.6 million in Q1 2026, $254.5 million in Q4 2025, and $57.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 248.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 248.20 Mn |
| Mar 31, 2026 | 336.60 Mn |
| Dec 31, 2025 | 254.54 Mn |
| Sep 30, 2025 | 57.51 Mn |
| Jun 30, 2025 | -686.39 Mn |
| Mar 31, 2025 | -55.90 Mn |
| Dec 31, 2024 | 190.77 Mn |
| Sep 30, 2024 | 260.21 Mn |
| Jun 30, 2024 | 199.44 Mn |
| Mar 31, 2024 | 66.21 Mn |
| Dec 31, 2023 | 122.50 Mn |
| Sep 30, 2023 | 172.39 Mn |
| Jun 30, 2023 | 157.64 Mn |
| Mar 31, 2023 | 126.06 Mn |
| Dec 31, 2022 | -263.39 Mn |
| Sep 30, 2022 | 24.76 Mn |
| Jun 30, 2022 | 85.55 Mn |
| Mar 31, 2022 | 87.55 Mn |
| Dec 31, 2021 | 49.38 Mn |
| Sep 30, 2021 | 28.37 Mn |